US 12,226,525 B2
Nasolacrimal drainage system implants for drug therapy
Eugene de Juan, Jr., San Francisco, CA (US); Stephen Boyd, Murrieta, CA (US); Cary J. Reich, Los Gatos, CA (US); Alan R. Rapacki, Redwood City, CA (US); Hanson S. Gifford, Woodside, CA (US); and Mark Deem, Mountain View, CA (US)
Assigned to Mati Therapeutics, Inc.
Filed by Mati Therapeutics, Inc.
Filed on Dec. 24, 2020, as Appl. No. 17/133,980.
Application 17/133,980 is a continuation of application No. 16/544,884, filed on Aug. 19, 2019, granted, now 10,874,606.
Application 16/544,884 is a continuation of application No. 16/168,554, filed on Oct. 23, 2018, granted, now 10,300,014, issued on May 28, 2019.
Application 16/168,554 is a continuation of application No. 15/852,619, filed on Dec. 22, 2017, granted, now 10,383,817, issued on Aug. 20, 2019.
Application 15/852,619 is a continuation of application No. 15/405,991, filed on Jan. 13, 2017, granted, now 9,849,082, issued on Dec. 26, 2017.
Application 15/405,991 is a continuation of application No. 14/858,555, filed on Sep. 18, 2015, granted, now 9,549,852, issued on Jan. 24, 2017.
Application 14/858,555 is a continuation of application No. 14/265,071, filed on Apr. 29, 2014, granted, now 9,168,222, issued on Oct. 27, 2015.
Application 14/265,071 is a continuation of application No. 13/184,690, filed on Jul. 18, 2011, granted, now 8,747,884, issued on Jun. 10, 2014.
Application 13/184,690 is a continuation of application No. 11/695,545, filed on Apr. 2, 2007, granted, now 7,998,497, issued on Aug. 16, 2011.
Claims priority of provisional application 60/871,864, filed on Dec. 26, 2006.
Claims priority of provisional application 60/787,775, filed on Mar. 31, 2006.
Prior Publication US 2021/0212941 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61F 9/00 (2006.01); A61F 9/007 (2006.01); A61K 9/06 (2006.01); A61K 31/215 (2006.01); A61K 31/216 (2006.01); A61K 31/55 (2006.01); A61K 31/557 (2006.01); A61K 31/5575 (2006.01); A61K 31/573 (2006.01); A61K 47/34 (2017.01); A61L 31/16 (2006.01)
CPC A61K 9/0051 (2013.01) [A61F 9/0017 (2013.01); A61F 9/0026 (2013.01); A61F 9/00772 (2013.01); A61F 9/00781 (2013.01); A61K 9/00 (2013.01); A61K 9/0017 (2013.01); A61K 9/06 (2013.01); A61K 31/215 (2013.01); A61K 31/216 (2013.01); A61K 31/55 (2013.01); A61K 31/557 (2013.01); A61K 31/5575 (2013.01); A61K 31/573 (2013.01); A61K 47/34 (2013.01); A61L 31/16 (2013.01); A61F 2220/0008 (2013.01); A61F 2250/0067 (2013.01); A61F 2250/0087 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method for delivery of a therapeutic agent to an eye of a patient using a punctal plug, comprising:
positioning the punctal plug into a lacrimal punctum of an eye wherein the punctal plug comprises a plug body and a drug insert, wherein the drug insert comprises a drug core comprising a therapeutic agent and a polymer matrix, and wherein the plug body comprises silicone; and,
an impermeable sheath body partially covering the drug core, wherein the sheath body is configured to provide an exposed proximal end of the drug core in direct contact with tear fluid that releases the therapeutic agent to the eye; and,
delivering a dose of the therapeutic agent to the eye for a sustained treatment period, wherein the punctal plug remains in position for the sustained treatment period for at least of one week to 3 months.